Kemwell Biopharma Profile
Key Indicators
- Authorised Capital ₹ 240.00 Cr
as on 04-12-2024
- Paid Up Capital ₹ 5.13 Cr
as on 04-12-2024
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 50.00 Cr
as on 04-12-2024
- Satisfied Charges ₹ 250.11 Cr
as on 04-12-2024
- Revenue 68.05%
(FY 2022)
- Profit -95.91%
(FY 2022)
- Ebitda 520.54%
(FY 2022)
- Net Worth 2.23%
(FY 2022)
- Total Assets 6.08%
(FY 2022)
About Kemwell Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 240.00 Cr and a paid-up capital of Rs 5.13 Cr.
The company currently has active open charges totaling ₹50.00 Cr. The company has closed loans amounting to ₹250.11 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anurag Bagaria, Shriram Chandak, and Neha Bagaria serve as directors at the Company.
- CIN/LLPIN
U24232KA2008PTC046341
- Company No.
046341
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2008
- Date of AGM
13 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Kemwell Biopharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anurag Bagaria  | Director | 07-May-2008 | Current |
| Shriram Chandak | Director | 08-Mar-2010 | Current |
| Neha Bagaria | Director | 21-Jun-2024 | Current |
Financial Performance and Corporate Structure Insights of Kemwell Biopharma.
Kemwell Biopharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 68.05% increase. The company also saw a substantial fall in profitability, with a 95.91% decrease in profit. The company's net worth moved up by a moderate rise of 2.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kemwell Biopharma?
In 2022, Kemwell Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- North East Gases Pvt LtdActive 53 years 3 months
Anurag Bagaria and Shriram Chandak are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Aug 2024 | ₹50.00 Cr | Open |
Citi Bank N.A. Creation Date: 31 Mar 2012 | ₹4.75 Cr | Satisfied |
State Bank Of India Creation Date: 20 Jul 2011 | ₹220.07 Cr | Satisfied |
How Many Employees Work at Kemwell Biopharma?
Kemwell Biopharma has a workforce of 291 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kemwell Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kemwell Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
